Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Avelumab in MMR-deficient or POLE-mutated Metastatic Colorectal Cancer
KCT0003561Phase 2Completed
- Sponsor
- Ministry of Health & Welfare
- Start
- May 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in metastatic colon cancer (mCRC), sponsored by Ministry of Health & Welfare. Started May 2017; status: completed.
02
Drugs
avelumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on KCT0003561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003561.